Current treatment of follicular non-Hodgkin's lymphoma (Q34666779)

3 August 2017

1 reference

title

Current treatment of follicular non-Hodgkin's lymphoma (English)

1 reference

3 August 2017

Reiser M

1

1 reference

PubMed ID

12044501

3 August 2017

Diehl V

series ordinal

2

1 reference

3 August 2017

1 June 2002

1 reference

European Journal of Cancer

3 August 2017

1 reference

3 August 2017

38

1 reference

3 August 2017

9

1 reference

3 August 2017

1167-1172

1 reference

3 August 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Long-term results with radiotherapy for Stage I-II follicular lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Treatment of non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and Prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Fludarabine phosphate in lymphoma: an important new therapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900087-4

7 January 2021

10.1016/S0959-8049(02)00087-4

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12044501